Anti-TGF-beta monoclonal antibody GC1008
| Anti-TGF-beta monoclonal antibody GC1008 | |
|---|---|
| Term | Anti-TGF-beta monoclonal antibody GC1008 |
| Short definition | anti-TGF-beta monoclonal antibody GC1008 (AN-tee. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
anti-TGF-beta monoclonal antibody GC1008 - (pronounced) (AN-tee. . . BAY-tuh MAH-noh-KLOH-nul AN-tee-BAH-dee. . . ) substance being studied to treat breast cancer that has spread to other parts of the body. It is also being studied in the treatment of other cancers and diseases. The anti-TGF-beta monoclonal antibody GC1008 binds to a protein called transforming growth factor-beta (TGF-beta) found on some cancer cells. The anti-TGF-beta monoclonal antibody GC1008 can help prevent cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow. It's a type of monoclonal antibody and a type of anti-angiogenesis drug. Also called fresolimumab and GC1008
External links
- Medical encyclopedia article on Anti-TGF-beta monoclonal antibody GC1008
- Wikipedia's article - Anti-TGF-beta monoclonal antibody GC1008
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski